Viral Gastroenteritis Market Report 2026

Viral Gastroenteritis Market Overview

• Viral Gastroenteritis market size has reached to $7.06 billion in 2025 • Expected to grow to $9.2 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Prevalence Of Gastrointestinal Disorders To Drive Market Growth • Market Trend: Innovative PCR Kits Reshaping The Viral Gastroenteritis Market • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Viral Gastroenteritis Market?

Viral gastroenteritis is an intestinal viral infection characterized by swelling, irritation, and inflammation of the inner lining of your gastrointestinal tract. The signs and symptoms include watery diarrhea, nausea or vomiting, stomach cramps, and a fever. The main types of drugs in viral gastroenteritis are antibiotics, antacids, laxatives, antimotility agents, and others. Antacids refer to medicines that neutralize the acid in the stomach to relieve heartburn and indigestion. The various diagnosis includes a physical examination and a rapid stool test that is indicated by various indications such as watery diarrhea, abdominal cramps, pain, and others. The various types of viruses include norovirus, rotavirus, astrovirus, and enteric adenovirus. These are used by various end-users such as hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers, and others.

What Is The Viral Gastroenteritis Market Growth Forecast?

The viral gastroenteritis market size is expected to see strong growth in the next few years. It will grow to $9.2 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing investments in infectious disease surveillance, rising demand for rapid point-of-care diagnostics, expansion of vaccination and prevention programs, growing focus on pediatric healthcare, increasing adoption of digital disease monitoring. Major trends in the forecast period include increasing focus on rapid diagnostic testing, rising demand for supportive care therapies, growing emphasis on infection control and prevention, expansion of oral rehydration and zinc therapy usage, enhanced surveillance of viral outbreaks.

Global Viral Gastroenteritis Market Segmentation

1) By Drugs: Antibiotics, Antacids, Antimotility Agents, Others Drugs 2) By Diagnosis: Physical Examination, Rapid Stool Test 3) By Indication: Watery Diarrhea, Abdominal Cramps, Pain, Other Indications 4) By Type Of Virus: Norovirus, Rotavirus, Astrovirus, Enteric Adenovirus 5) By End User: Hospitals, Clinics, Pharmaceutical Companies, Diagnostic Centers, Ambulatory Care Centers, Others End Users Subsegments: 1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Penicillins, Macrolides, Cephalosporins 2) By Antacids: Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2 Blockers), Magnesium-Based Antacids, Calcium-Based Antacids, Sodium Bicarbonate 3) By Antimotility Agents: Loperamide, Diphenoxylate 4) By Other Drugs: Oral Rehydration Salts (Ors), Zinc Supplements, Antiemetics

What Is The Driver Of The Viral Gastroenteritis Market?

The increasing prevalence of gastrointestinal disorders is expected to propel the growth of the viral gastroenteritis market going forward. Gastrointestinal (GI) disorders refer to a disease that occurs within or on any part of the gastrointestinal tract. Viral gastroenteritis drugs and diagnosis treatments help people suffering from the illness with proper and appropriate medication. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the IBD Clinical and Research Centre, a Canada-based organization that aims to improve the lives of patients with Crohn's disease and ulcerative colitis, with a prevalence of 825 per 100,000 in 2023, over 320,000 people in Canada have inflammatory bowel disease (IBD), and as the prevalence is expected to increase by 2.44% annually, 1.1% of the population, or 470,000 Canadians, is projected to be living with IBD by 2035. Therefore, the increasing prevalence of gastrointestinal disorders is driving the growth of the viral gastroenteritis industry.

Key Players In The Global Viral Gastroenteritis Market

Major companies operating in the viral gastroenteritis market are Pfizer Inc., Sanofi S A, Abbott Laboratories, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Mylan N V, Dr Reddys Laboratories Ltd, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, ANI Pharmaceuticals Inc, Merck Sharp & Dohme Corp, Abbvie Inc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Roche Holding AG, BristolMyersSquibb Company, Amgen Inc, Eli Lilly and Company, Novartis AG, Johnson and Johnson, Moderna Inc, Bharat Biotech International Ltd

Global Viral Gastroenteritis Market Trends and Insights

Major companies operating in the viral gastroenteritis market are developing new products such as PCR kits for gastrointestinal infectious diseases to gain a competitive edge in the market. PCR kits, or Polymerase Chain Reaction kits, are molecular biology tools designed for the amplification and detection of specific DNA sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based molecular diagnostic solutions company, launched 10 Real-Time PCR Kits designed for accurate detection of gastrointestinal pathogens, forming a comprehensive Total PCR Solution when integrated with their extraction solution and PCR system. The Real-Time PCR Kits cover a range of bacterial, viral, and parasitic pathogens associated with gastrointestinal infections. These include diseases caused by various bacterial pathogens such as Campylobacter, Salmonella, Shigella, and Clostridioides difficile, as well as viral agents like Adenovirus, Rotavirus, Astrovirus, and Norovirus. This innovative solution provides a streamlined approach from sample pre-processing to PCR amplification analysis.

What Are Latest Mergers And Acquisitions In The Viral Gastroenteritis Market?

In January 2024, HilleVax Inc., a Switzerland-based biotech company, collaborated with Chengdu Kanghua Biological Products Co. Ltd. Through this collaboration, HilleVax Inc. aims to develop HIL-216, a next-generation norovirus vaccine that targets six common genotypes, with clinical trials set to begin in 2024 following FDA clearance. Kanghua Biological Products Co. Ltd. is a China-based firm focused on developing and manufacturing biological products and vaccines for veterinary and human health.

Regional Outlook

North America was the largest region in the viral gastroenteritis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Viral Gastroenteritis Market?

The viral gastroenteritis market consists of revenues earned by entities by providing various diagnostics such as polymerase chain reaction testing and immunoassays. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral gastroenteritis market also includes sales of antiemetics, and chemotherapy drugs used for treating viral gastroenteritis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Gastroenteritis Market Report 2026?

The viral gastroenteritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral gastroenteritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.